Ketamine vs SSRIs: How They Compare for Treating Depression

Overview

Selective serotonin reuptake inhibitors (SSRIs) have been the cornerstone of depression pharmacotherapy since fluoxetine's approval in 1987. Medications in this class — including sertraline, escitalopram, paroxetine, citalopram, and fluvoxamine — are prescribed to tens of millions of patients worldwide and represent the default first-line treatment recommended by every major clinical guideline.

Ketamine, by contrast, entered the psychiatric landscape much more recently. Although it has been used as an anesthetic since 1970, its rapid antidepressant properties were first demonstrated in a controlled clinical trial in 2000. Since then, ketamine has emerged as one of the most significant advances in depression treatment, particularly for patients with treatment-resistant depression (TRD) who have not responded to SSRIs and other conventional medications.

Mechanism of Action

SSRIs work by blocking the serotonin transporter (SERT) in the synaptic cleft, preventing the reuptake of serotonin back into the presynaptic neuron. This increases the concentration of serotonin available to bind postsynaptic receptors. Over time — typically two to six weeks — this sustained increase in serotonergic signaling triggers adaptive changes in receptor sensitivity and downstream gene expression that gradually produce antidepressant effects. The exact mechanism by which increased serotonin availability translates into mood improvement remains incompletely understood.

Ketamine operates through an entirely different neurotransmitter system. It blocks NMDA receptors in the glutamatergic system, the brain's primary excitatory network. By preferentially blocking NMDA receptors on GABAergic interneurons, ketamine triggers a cascade of events: a glutamate surge, AMPA receptor activation, BDNF release, mTOR pathway activation, and rapid synaptogenesis — the formation of new synaptic connections in the prefrontal cortex and hippocampus. This mechanism directly repairs the synaptic damage caused by chronic stress and depression.

Onset of Action

This is perhaps the most dramatic difference between the two treatments.

SSRIs typically require two to six weeks of daily use before patients experience meaningful symptom improvement. Some patients require eight to twelve weeks at full therapeutic doses before response can be adequately assessed. During this waiting period, patients may experience side effects without corresponding benefit, which contributes to high rates of early discontinuation.

Ketamine can produce measurable antidepressant effects within hours of a single sub-anesthetic dose. Multiple studies have documented significant improvement in depression scores within two to four hours of an IV infusion, with peak effects occurring at approximately 24 hours. This rapid onset is particularly valuable in acute settings, such as suicidal crises, where the weeks-long delay associated with SSRIs is clinically unacceptable.

Efficacy

SSRIs produce remission (complete symptom resolution) in approximately 30 to 37 percent of patients in their first adequate trial, according to the STAR*D study. Response rates (at least 50 percent symptom reduction) are somewhat higher, in the range of 40 to 60 percent. For patients who do not respond to the first SSRI, switching to another SSRI or a different antidepressant class yields progressively lower remission rates with each subsequent trial.

Ketamine demonstrates response rates of approximately 50 to 70 percent in treatment-resistant populations — patients who have already failed multiple SSRI trials. Remission rates with ketamine range from 25 to 40 percent in TRD, which is notable given that these patients represent the most difficult-to-treat population. However, ketamine's effects are typically transient, lasting days to weeks after a single treatment, requiring repeated sessions to maintain benefit.

Side Effects

SSRIs commonly cause sexual dysfunction (reduced libido, difficulty achieving orgasm), weight gain, gastrointestinal symptoms (nausea, diarrhea), insomnia or somnolence, headache, and emotional blunting. These effects can be persistent for as long as the patient takes the medication, and some (particularly sexual side effects) affect a large proportion of users. Discontinuation syndrome — withdrawal-like symptoms when SSRIs are stopped abruptly — is another significant concern.

Ketamine produces transient side effects that are qualitatively different: dissociation, dizziness, nausea, elevated blood pressure, and perceptual changes. These effects typically resolve within one to two hours after treatment and do not persist between sessions. Ketamine does not cause sexual dysfunction or weight gain. However, the potential for misuse and the need for clinical monitoring during administration represent distinct concerns.

Duration and Maintenance

SSRIs are designed for daily, long-term use. Most guidelines recommend continuing SSRI treatment for at least six to twelve months after remission, and many patients take them for years or indefinitely. This daily regimen provides continuous symptom management but requires ongoing adherence and tolerance of persistent side effects.

Ketamine is typically administered in acute series (often six treatments over two to three weeks) followed by maintenance sessions at varying intervals — weekly, biweekly, or monthly depending on individual response. The optimal maintenance schedule has not been definitively established, and there is considerable patient-to-patient variability in how long the antidepressant effects persist after each treatment.

Cost and Access

SSRIs are available as generic medications and are among the least expensive drugs in all of medicine — often costing under $10 per month. They are universally covered by insurance and can be prescribed by any licensed provider.

Ketamine treatment costs significantly more. IV infusion sessions typically range from $300 to $800 per session without insurance, and most insurers do not cover off-label ketamine therapy. The branded esketamine nasal spray is covered by some insurers for TRD but carries a list price exceeding $500 per session. For a full breakdown of costs across methods, see our ketamine therapy cost guide. Compounded oral and sublingual ketamine formulations are less expensive but still represent a greater financial commitment than SSRIs.

When Each Treatment Is Appropriate

SSRIs remain the appropriate first-line treatment for most patients diagnosed with major depressive disorder. Their extensive safety record, low cost, ease of use, and broad efficacy make them the rational starting point.

Ketamine is most appropriate for patients who have failed adequate trials of SSRIs and other conventional antidepressants — those meeting criteria for treatment-resistant depression. It is also increasingly considered for acute suicidal ideation, where its rapid onset can be life-saving, and for patients who cannot tolerate the weeks-long delay of SSRI onset.

The two treatments are not mutually exclusive. Many patients continue their SSRI (or other antidepressant) while receiving ketamine therapy, as the combination has been shown to be safe and may provide complementary benefit.

References

• STAR*D Trial Results — Rush et al. (2006), American Journal of Psychiatry. Definitive data on SSRI remission rates.
• A Randomized Trial of an NMDA Antagonist in Treatment-Resistant Depression — Zarate et al. (2006), Archives of General Psychiatry. Landmark ketamine trial in TRD.
• Efficacy of Ketamine vs SSRIs for Depression: A Meta-Analysis — Bahji et al. (2020), Journal of Psychiatric Research. Comparative efficacy review.
• NIMH Depression Treatment Information — National Institute of Mental Health overview of depression treatment options.
• WHO Model List of Essential Medicines — World Health Organization listing including both ketamine and SSRIs.